文献速递消化道肿瘤与早癌

复发性移码新抗原疫苗在Lynch综合征小鼠模型中诱导保护性免疫并降低肿瘤负荷、改善总生存

Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
PubMed 文献 · Gastroenterology · 2021-07-02

该研究基于小鼠编码单核苷酸重复序列数据库筛选共享移码肽(FSP)新抗原,鉴定出4个可诱导CD4/CD8 T细胞应答的FSP。在肠道特异性Msh2敲除的VCMsh2小鼠中,4个FSP联合接种显著增强特异性适应性免疫、减少肠道肿瘤负荷并延长总生存;联合每日萘普生可进一步增强免疫应答、延缓肿瘤生长并更有效延长生存。

要点

  • 4个共享FSP新抗原可在naïve C57BL/6小鼠诱导CD4/CD8 T细胞应答。
  • VCMsh2小鼠中4个FSP联合接种降低肠道肿瘤负荷并延长总生存。
  • FSP疫苗联合每日萘普生较单用疫苗更有效增强免疫、延缓肿瘤生长和延长生存。

核心结论

  • 临床前 findings 支持将复发性FSP新抗原疫苗接种作为Lynch综合征癌症免疫预防的临床策略。

研究设计与样本

  • 建立包含488,235个小鼠编码单核苷酸重复序列的全基因组数据库,基于重复长度、基因表达和突变频率筛选候选FSP。
  • 采用计算机预测、体内免疫原性测试和表位定位鉴定FSP疫苗候选。
  • 在naïve C57BL/6小鼠中测试FSP诱导的T细胞应答,在肠道条件性敲除Msh2的VCMsh2小鼠中评估疫苗接种效果。

主要发现

  • 鉴定出4个共享FSP新抗原:Nacad(FSP-1)、Maz(FSP-1)、Senp6(FSP-1)、Xirp1(FSP-1),可在naïve C57BL/6小鼠诱导CD4/CD8 T细胞应答。
  • VCMsh2小鼠中仅4个FSP联合接种显著增加FSP特异性适应性免疫、减少肠道肿瘤负荷并延长总生存。
  • FSP疫苗接种联合每日萘普生治疗增强免疫应答、延缓肿瘤生长并比单用FSP疫苗更有效延长生存。

临床怎么用

  • 在Lynch综合征高MSI肿瘤风险人群中,复发性FSP新抗原疫苗可作为候选免疫预防策略。
  • FSP疫苗与萘普生联合可能增强免疫应答和抗肿瘤效果,但需临床验证。

局限性

  • 本研究为临床前小鼠模型研究,结果尚未在人体中验证。
  • 原文未报告FSP疫苗在Lynch综合征患者中的癌症预防效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: DNA mismatch repair deficiency drives microsatellite instability (MSI). Cells with MSI accumulate numerous frameshift mutations. Frameshift mutations affecting cancer-related genes may promote tumorigenesis and, therefore, are shared among independently arising MSI tumors. Consequently, such recurrent frameshift mutations can give rise to shared immunogenic frameshift peptides (FSPs) that represent ideal candidates for a vaccine against MSI cancer. Pathogenic germline variants of mismatch repair genes cause Lynch syndrome (LS), a hereditary cancer syndrome affecting approximately 20-25 million individuals worldwide. Individuals with LS are at high risk of developing MSI cancer. Previously, we demonstrated safety and immunogenicity of an FSP-based vaccine in a phase I/IIa clinical trial in patients with a history of MSI colorectal cancer. However, the cancer-preventive effect of FSP vaccination in the scenario of LS has not yet been demonstrated. METHODS: A genome-wide database of 488,235 mouse coding mononucleotide repeats was established, from which a set of candidates was selected based on repeat length, gene expression, and mutation frequency. In silico prediction, in vivo immunogenicity testing, and epitope mapping was used to identify candidates for FSP vaccination. RESULTS: We identified 4 shared FSP neoantigens (Nacad [FSP-1], Maz [FSP-1], Senp6 [FSP-1], Xirp1 [FSP-1]) that induced CD4/CD8 T cell responses in naïve C57BL/6 mice. Using VCMsh2 mice, which have a conditional knockout of Msh2 in the intestinal tract and develop intestinal cancer, we showed vaccination with a combination of only 4 FSPs significantly increased FSP-specific adaptive immunity, reduced intestinal tumor burden, and prolonged overall survival. Combination of FSP vaccination with daily naproxen treatment potentiated immune response, delayed tumor growth, and prolonged survival even more effectively than FSP vaccination alone. CONCLUSIONS: Our preclinical findings support a clinical strategy of recurrent FSP neoantigen vaccination for LS cancer immunoprevention.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Gebert J, Gelincik O, Oezcan-Wahlbrink M, et al. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology. 2021. PMID: 34224739. doi:10.1053/j.gastro.2021.06.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。